Factors contributing to multidrug-resistant tuberculosis among sputum culture-positive pulmonary tuberculosis patients in Indonesia: A cross-sectional study

Abstract

Objective: To analyze the risk factors associated with multidrug- resistant tuberculosis (MDR-TB) as a first national survey in Indonesia.

Methods: This national coverage cross-sectional study was conducted from 2017 to 2018. The study subjects were selected using a multi-stage probability random sampling method. MDR- TB is tuberculosis caused by bacteria resistant to at least isoniazid and rifampicin. The dependent variable was MDR-TB. Independent variables included age, sex, education, employment status, place of residence, history of living with TB patients, and the number of household members. Univariate and multivariate logistic regression models were used to analyze the risk factors associated with MDR- TB. All the data were analyzed using STATA V.14.0 (Stata Corp LLC, College Station, TX).

Results: This study found the MDR rate was 109/3 234 (3.4%) among positive pulmonary TB patients. More than twice as many patients had MDR re-treatment (74/3 234, 2.3%), compared to 35/3 234 (1.1%) who had new TB diagnoses or were getting initial treatment. After adjusting for employment status, individuals with a prior history of tuberculosis treatment were found to have significantly higher odds of developing MDR-TB, with an odds ratio of 7.22 (95% CI 3.87-13.44).

Conclusions: Increasing attention should be paid to these patients to prevent MDR-TB, and MDR-TB transmission is an urgent challenge for controlling TB worldwide. Early detection of MDR-TB is a critical part of TB control programs.

Keywords

Multi-drug resistance / Tuberculosis / Risk factors / Indonesia

References

[1] World Health Organization. Global tuberculosis report 2024. [Online]. Available from: https://iris.who.int/bitstream/handle/10665/379339/9789240101531-eng.pdf?sequence=1. [Accessed on 4 July 2025].

[2] Diriba G, Tola HH, Alemu A, Yenew B, Gamtesa DF, Kebede A. Drug resistance and its risk factors among extrapulmonary tuberculosis in Ethiopia: A systematic review and meta-analysis. PLoS One 2021; 16(10): e0258295.

[3] Mulu W, Mekonnen D, Yimer M, Admassu A, Abera B. Risk factors for multidrug resistant tuberculosis patients in amhara national regional state. Afr Health Sci 2015; 15(2): 368-377.

[4] Caminero JA, Cayla JA, García-García JM, García-Pérez FJ, Palacios JJ, Ruiz-Manzano J. Diagnosis and treatment of drug-resistant tuberculosis. Arch Bronconeumol 2017; 53(9): 501-509.

[5] World Health Organization. Global tuberculosis report. 2020. [Online]. Available from: https://doi.org/10.1787/f494a701-en. [Accessed on 4 March 2025].

[6] Seung KJ, Keshavjee S, Rich ML. Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. Cold Spring Harb Perspect Med 2015; 5(9): 1-20.

[7] Dean AS, Zignol M, Cabibbe AM, Falzon D, Glaziou P, Cirillo DM, et al. Prevalence and genetic profiles of isoniazid resistance in tuberculosis patients: A multicountry analysis of cross-sectional data. PLoS Med 2020; 17(1): 1-13.

[8] Becerra MC, Appleton S, Franke MF, Chalco K, Bayona J, Murray MB, et al. ASC. Recurrence after treatment for pulmonary multidrug-resistant tuberculosis. Clin Infect Dis 2010: 51(6): 709-711.

[9] Hang NT Le, Maeda S, Lien LT, Thuong PH, Van Hung N, Thuy TB, et al. Primary drug-resistant tuberculosis in Hanoi, Viet Nam: Present status and risk factors. PLoS One 2013; 8(8): 1-9. e71867.

[10] Choi H, Mok J, Kang YA, Kim HS, Jeon D, Jeong D, et al. Retreatment after loss to follow-up reduces mortality in patients with multidrug/rifampicin-resistant tuberculosis. ERJ Open Res 2023; 9(4): 1-10.

[11] Lolong DB, Aryastami NK, Kusrini I, Tobing KL, Tarigan I, Isfandari S, et al. Non-adherence to anti-tuberculosis treatment, reasons and associated factors among pulmonary tuberculosis patients in the communities in Indonesia. PLoS One 2023; 18(8): e0287628.

[12] Allwood BW, Byrne A, Meghji J, Rachow A, Van Der Zalm MM, Schoch OD. Post-tuberculosis lung disease: Clinical review of an under-recognised global challenge. Resp Int Rev Thoracic Dis 2021; 100(8): 751-763.

[13] Tiberi S, Utjesanovic N, Galvin J, Centis R, D’Ambrosio L, van den Boom M, et al. Drug resistant TB–latest developments in epidemiology, diagnostics and management. Int J Infect Dis 2022; 124(Suppl 1): S20-S25.

[14] Franke MF, Appleton SC, Mitnick CD, Furin JJ, Bayona J, Chalco K, et al. Aggressive regimens for multidrug-resistant tuberculosis reduce recurrence. Clin Infect Dis 2013; 56(6): 770-776.

[15] Getnet F, Sileshi H, Seifu W, Yirga S, Alemu AS. Do retreatment tuberculosis patients need special treatment response follow-up beyond the standard regimen? Finding of five-year retrospective study in pastoralist setting. BMC Infect Dis 2017; 17(1): 762.

[16] World Health Organization. Guidelines for surveillance of drug resistance in tuberculosis. Geneva: WHO Press; 2015. [Online]. Available from: https://iris.who.int/bitstream/handle/10665/174897/9789241549134_eng.pdf?sequence=1. [Accessed on 17 July 2025].

[17] Iem V, Dean A, Zignol M, Vongvichit P, Inthavong D, Siphanthong S, et al. Low prevalence of MDR-TB in Lao PDR: Results from the first national anti-tuberculosis drug resistance survey. Trop Med Int Health 2019; 24(4): 421-431.

[18] Wang Z, Hou Y, Guo T, Jiang T, Xu L, Hu H, et al. Epidemiological characteristics and risk factors of multidrug-resistant tuberculosis in Luoyang, China. Front Public Health 2023; 11: 1117101.

[19] VanderWeele TJ. Principles of confounder selection. Eur J Epidemiol 2019; 34: 211-219.

[20] Stosic M, Vukovic D, Babic D, Antonijevic G, Foley KL, Vujcic I, et al. Risk factors for multidrug-resistant tuberculosis among tuberculosis patients in Serbia: A case-control study. BMC Public Health 2018; 18(1): 1-8.

[21] Oyedeji GJ, Adeyemo C, Dissou A, Abiodun T, Alli OAT, Onaolapo OJ, et al. Prevalence of multi-drug resistant tuberculosis among tuberculosis patients attending chest clinics in Osun-State, Nigeria. Curr Pharm Biotechnol 2020; 21(10): 939-947.

[22] Inayati , Nurmala QP, Nugroho H. Tuberculosis treatment history influenced multidrug-resistant tuberculosis (MDR-TB) incidence based on gene-xpert examination. In: Iman Permana, Erna Rochmawati (eds.) Proceedings of the International Conference on Sustainable Innovation on Health Sciences and Nursing (ICOSI-HSN 2022). Atlantis: Atlantis Press; 2022, p. 21-27.

[23] Soedarsono S, Mertaniasih NM, Kusmiati T, Permatasari A, Ilahi WK, Anggraeni AT. Characteristics of previous tuberculosis treatment history in patients with treatment failure and the impact on acquired drug-resistant tuberculosis. Antibiotics (Basel) 2023; 12(3): 598.

[24] Sichen L, Rui W, Yue Y, Xin L, Youbin C, Ze T, et al. Analysis of drug resistance in pulmonary tuberculosis patients with positive sputum tuberculosis culture in Northeast China. Front Pharmacol 2023; 14: 1263726.

[25] Reta MA, Tamene BA, Abate BB, Mensah E, Maningi NE, Fourie PB. Mycobacterium tuberculosis drug resistance in Ethiopia: An updated systematic review and meta-analysis. Trop Med Infect Dis 2022; 7(10): 300.

[26] Badgeba A, Shimbre MS, Gebremichael MA, Bogale B, Berhanu M, Abdulkadir H. Determinants of multidrug-resistant Mycobacterium tuberculosis infection: A multicenter study from southern Ethiopia. Infect Drug Resist 2022; 15: 3523-3535.

[27] Mansoori N, Pahlavanzadeh B, Atarjalali M. Risk factors associated with multidrug-resistant tuberculosis in areas with a moderate tuberculosis burden. Int Health 2025; 17(2): 186-194.

[28] Kusumandari PV, Sunarti S, Nawangsari D. The influence of TB patient treatment history on the incidence of MDR-TB at Prof. Dr. Margono Soekarjo Regional Hospital. Pharmacy Genius 2023; 2(3): 176-188.

[29] Zhang C, Wang Y, Shi G, Han W, Zhao H, Zhang H, et al. Determinants of multidrug-resistant tuberculosis in Henan province in China: A case control study. BMC Public Health 2016; 16(42): 1-8. doi: 10.1186/s12889-016-2711-z.

[30] Przybylski G, Dbrowska A, Pilaczyńska-Cemel M, Krawiecka D. Unemployment in TB patients: Ten-year observation at regional center of pulmonology in bydgoszcz, Poland. Med Sci Monit 2014; 20: 2125-2131.

[31] Vanderweele TJ, Shpitser I. A new criterion for confounder selection. Biometrics 2011; 67(4): 1406-1413.

[32] Altman DG, Bland MJ. Absence of evidence is not evidence of absence. [Online]. Available from: https://pubmed.ncbi.nlm.nih.gov/7647644/. [Accessed 4 July 2025].

[33] Wasserstein RL, Lazar NA. The ASA’s statement on p-values: Context, process, and purpose. Am Stat 2016; 70(2): 129-133.

[34] Burnham KP, Anderson DR. Multimodel inference: Understanding AIC and BIC in model selection. Sociol Methods Res 2004; 33: 261-304.

[35] Truzyan N, Crape B, Grigoryan R, Martirosyan H, Petrosyan V. Increased risk for multidrug-resistant tuberculosis in migratory workers, Armenia. Emerg Infect Dis 2015; 21(3): 474-476.

[36] Azmiardi A, Saefurrohim MZ, Ardiani IH. The relationship between age, employment status, gender, linezolid use, and HIV status on the survival duration of short-term treated MDR-TB patients. Panakeia J Public Health 2024; 1(1): 1-7.

[37] Khan R. The social determinants of multidrug resistant tuberculosis in the United States Between 2005 and 2009. [Online]. Available from: https://core.ac.uk/download/71424151.pdf. [Accessed 4 March 2025].

[38] Pontali E, Raviglione MC, Migliori GB, Akkerman OW, Alffenaar JW, Blanc FX, et al. Regimens to treat multidrug-resistant tuberculosis: Past, present and future perspectives. Eur Respir Rev 2019; 28(152): 190035.

[39] Jiang WX, Huang F, Tang SL, Wang N, Du X, Zhang H, et al. Implementing a new tuberculosis surveillance system in Zhejiang, Jilin and Ningxia: Improvements, challenges and implications for China’s National Health Information System. Infect Dis Poverty 2021; 10(1): 22.

[40] Liang S, Ma J, Wang G, Shao J, Li J, Deng H, et al. The application of artificial intelligence in the diagnosis and drug resistance prediction of pulmonary tuberculosis. Front Med (Lausanne) 2022; 9: 935080. doi: 10.3389/fmed.2022.935080.

[41] Winardi W, Nalapraya WY, Sarifuddin S, Anwar S, Yufika A, Wibowo A, et al. Knowledge and attitudes of Indonesian general practitioners towards the isoniazid preventive therapy program in Indonesia. J Prev Med Public Health 2022; 55(5): 428-435.

[42] Pengpid S, Peltzer K. Knowledge, attitudes, and practices regarding tuberculosis in Timor-Leste: Results from the demographic and health Survey 2016. J Prev Med Public Health 2019; 52: 115-122.